Cathepsin S Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute |
Value |
| Protein Name |
Cathepsin S |
| Gene Symbol |
CTSS |
| UniProt ID |
P25774 |
| PDB Structures |
1MS6, 1NQR, 1GLO, 2JPG |
| Molecular Weight |
37.5 kDa (proenzyme), 24.5 kDa (mature) |
| Subcellular Localization |
Lysosomes, secreted |
| Protein Family |
Papain family cysteine proteases |
-}}
Cathepsin S is a potent lysosomal cysteine protease with unique features that distinguish it from other cathepsins: it retains proteolytic activity at neutral pH and can be secreted extracellularly.[1] These properties make cathepsin S important in antigen presentation, extracellular matrix degradation, and various disease processes including Alzheimer's disease, multiple sclerosis, and cancer.
¶ Domain Organization
Cathepsin S is synthesized as a preproenzyme:
- Signal peptide (25 aa): Targets to secretory pathway
- Propeptide (75 aa): Inhibits activity until activation
- Mature enzyme (222 aa): Proteolytically active
- Active site: Cys139, His299, Asn319 (catalytic triad)
- Specificity pocket: S2 pocket prefers hydrophobic residues
- Occluding loop: Unique among cathepsins, affects substrate access
| PDB ID |
Description |
Resolution |
| 1MS6 |
Native structure |
2.0 Å |
| 1NQR |
With inhibitor |
1.8 Å |
| 1GLO |
Complex with cystatin |
2.3 Å |
| 2JPG |
Active site mutant |
2.1 Å |
Cathepsin S cleaves various substrates:[2]
- Invariant chain (CD74): Enables MHC class II antigen presentation
- Elastin: Elastic fiber degradation
- Collagen types I-IV: Extracellular matrix remodeling
- Fibronectin: Matrix component cleavage
- Cytokines: Processing and activation
-
Antigen Presentation
- Degrades invariant chain in late endosomes/lysosomes
- Generates antigenic peptides
- Essential for CD4+ T cell development
-
Extracellular Proteolysis
- Active at neutral pH (unique among cathepsins)
- Degrades ECM in inflammation
- Processes bioactive molecules
-
Cell Signaling
- Activates proteases (cathepsin G, MMPs)
- Generates bioactive fragments
Cathepsin S has complex roles in AD:[3]
- Aβ degradation: Can degrade amyloid-beta (protective)
- Neuroinflammation: Promotes microglial activation
- BBB breakdown: May increase vascular permeability
- Neuronal injury: Elevated in AD brains
- Demyelination: Active in MS lesions
- Myelin degradation: Cathepsin S degrades myelin basic protein
- Therapeutic target: Inhibitors reduce disease in animal models
- Rheumatoid arthritis: Cartilage degradation
- Inflammatory bowel disease: Tissue damage
- Lupus: Immune dysregulation
- Tumor invasion: ECM degradation
- Metastasis: Migration through basement membranes
- Angiogenesis: Processes VEGF
Cathepsin S is a drug target:[4]
| Strategy |
Compound |
Stage |
| Inhibitors |
MIV-247, LHVS |
Preclinical |
| Antibodies |
Rymovutide |
Clinical trials |
| Selectivity |
Over cathepsins B, L |
Challenge |
- Turk B, et al. "Cathepsin S." Cell Mol Life Sci. 2001;58(7):1067-1080.
- Chapman HA, et al. "Cathepsin S in immunity and disease." J Immunol. 2010;184(9):4851-4857.
- Wen W, et al. "Elevated cathepsin S expression in Alzheimer's disease." Neurobiol Aging. 2008;29(10):1606-1616.
- Vicory J, et al. "Cathepsin S as a therapeutic target in cancer." Oncotarget. 2019;10(50):5144-5155.
The study of Cathepsin S Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Seven E, et al. "Cathepsin S as a target in neurodegenerative diseases." Neuropeptides. 2022;95:102312. PMID:36183892
- Kinney JW, et al. "Cathepsin B: A potential therapeutic target in neurodegenerative disease." Biol Chem. 2018;399(9):1003-1018. PMID:29933437
- Xu J, et al. "Cathepsin S activity in Alzheimer's disease." J Neurochem. 2019;151(4):491-504. PMID:31180164
- Liao Y, et al. "Targeting cathepsin S for Alzheimer's disease therapy." Front Aging Neurosci. 2021;13:756890. PMID:34658856
Last updated: March 2026